Drug delivery has become one of the most technically inventive areas of pharmaceutical science, producing increasingly elaborate platforms such as multifunctional nanoparticles, long-acting depots, 3D-printed dosage forms, implantable systems, and responsive materials. Yet the number of delivery technologies that successfully become routine clinical and commercial products remains small compared with the volume of experimental innovation. This mismatch creates a translational paradox at the centre of the field. This article argues that the paradox cannot be explained only by external barriers such as regulation, investment scarcity, or clinical conservatism. It also reflects an internal innovation logic that equates sophistication with value. In this logic, the most admired systems are often those with the most components, functions, triggers, layers, and claims of precision. The article develops an original critical theory of over-engineering in drug delivery. Over-engineering is defined as the addition of technical features, materials, control mechanisms, or architectural complexity beyond what is necessary for therapeutic function, manufacturability, usability, and economic viability. The central claim is that excessive complexity can reduce, rather than increase, translational probability. Through a critical theoretical synthesis of recent drug delivery and translational literature, the paper identifies mechanisms through which over-engineered systems become difficult to manufacture, characterise, regulate, finance, prescribe, and use. It argues that translational failure is not merely an unfortunate downstream event but is often designed into systems at the earliest conceptual stage. Complexity therefore becomes a hidden liability disguised as innovation. The article proposes a counter-logic of design simplification. This counter-logic does not reject sophisticated science, but it demands that sophistication be justified by translational necessity rather than aesthetic or academic appeal. The conclusion calls for a simplicity revolution in drug delivery, where the field learns to value robustness, manufacturability, usability, and patient access as highly as novelty.
Eurasian Academy of Medicine and Dentistry